Home pageBooks

Advances in Biopharmaceutical Technology in China

 

Authors: 46 Internationally Recognized Authors
Publishing: A Society for Industrial Microbiology and BioPlan Associates
Every organization has a China strategy, though for many of us it is simply “ignore it.” A great opportunity exists in working with China and implementing an effective company strategy. However, winning in Asia in the new millennium will require fundamental changes in partnerships between western and Asian companies. Every company faces the question “What should our China strategy be?” But to neglect China is to forego opportunities to gain efficiency in most of the things we are trying to do. China provides opportunities that allow us to do different things and not just do things differently. This volume provides an overview of the biopharmaceutical industry, and the state of technology. It will help the reader understand general business practice in China, analyze business opportunities and in identifying potential partners for working in China. It provides a ready reference for all aspects of the world of biopharmaceuticals in China, including general understanding, detailed technical and business descriptions, and detailed information on all types of organizations involved in biopharmaceuticals in China, whether they be companies (state owned or privately owned), universities, or government institutions. 1. Chapter 1: Introduction: A China Biopharmaceuticals Strategy 2. Chapter 2: An Overview of Biopharmaceutical Developments in China 3. Chapter 3: China's Healthcare System and the Demand for Biopharmaceutical Products 4. Chapter 4: China Pharmaceuticals Market Situation 2006 5. Chapter 5: Biopharmaceutical Strategy in China: An Analysis of Innovation, Financing Policies, Talent, and Strategic Considerations Through 2010 (11th 5-year Plan) 6. Chapter 6: Biopharmaceuticals in China: A Market, Import/Export, and Financial Review 7. Chapter 7: Pharmacy and Drug Administration in China 8. Chapter 8: Regulatory Requirements Applicable to Clinical Trials in China 9. Chapter 9: FDA Requirements Applicable to Testing and Manufacturing Pharmaceutical Products in China for the U. S. Market 10. Chapter 10: Protection and Enforcement of Biopharmaceutical Intellectual Property Rights in China - A Rapidly Evolving System 11. Chapter 11: Biopharmaceutical Industry Venture Capital Investment in Mainland China 12. Chapter 12: Drug Discovery and Development Partnerships: Outsourcing and Partnering with China 13. Chapter 13: Doing Business in China 14. Chapter 14: Current Status and Future Prospect of Biogeneric Companies in China 15. Chapter 15: Biopharmaceutical Products in China 16. Chapter 16: Chinese Bioindustry Parks: Evolution and Growth 17. Chapter 17: Organizations in China involved in Biopharmaceutical Research and Manufacturing 18. Chapter 18: Life Science and Health Science Education in China 19. Chapter 19: Biopharmaceutical Research Collaboration between Western and Chinese Life Science Organization: A Guide to Prospective Partnership 20. Chapter 20: Industrial Technology Developments for Chinese Biopharmaceuticals 21. Chapter 21: Therapeutic Proteins in China 22. Chapter 22: Vaccines in China: Status of the Chinese Vaccine Industry 23. Chapter 23: Biotechnology and Analytical Methods in the Modernization of Traditional Chinese Herbal Medicine 24. Chapter 24: CHINA Briefs (Miscellaneous Articles)

Odkazy:

OPPI, MPO, EU

CEBIO

  • CEBIO
  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina
  • ALIDEA

LinkedIn
TOPlist